Details For Selected Brain Tumor Treatment

Sponsored By

Cleveland Clinic Brain Tumor and Neuro-Oncology Center

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

		Phase:		Phase 1/2

		Treatment ID#:		1624 11500

		Age Group:		Adults Only

		Min Karnofsky Score:		60: Requires occasional assistance but is able to care for most of own needs

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Sometimes Allowed Histologically confirmed oligodendroglioma or mixed oligoastrocytoma Grade 2-4 Recurrent disease Failed prior surgery, radiotherapy, nitrosourea-based therapy, or temozolomide chemotherapy regimen Progressive disease by MRI or CT scan No more than 2 prior chemotherapy regimens No prior or concurrent significant intratumoral hemorrhage

		Last Updated:		06/26/2006

		Tumor Types:		Mixed Glioma Oligodendroglioma High Grade Oligodendroglioma Low Grade


		Comments:		No prior interstitial chemotherapy, including carmustine wafers, unless separate lesion seen on MRI outside of prior treatment field

		Treatment Type:		Chemotherapy

		Contact:		Toni Kay Mangskau-MN Clinical Trials Referral Coordinator Mayo Clinic Cancer Center - MN 200 First Street SW Rochester, MN 55905 USA Phone: (507)538-7623 Fax: E-mail: mangskau.toni@mayo.edu Website: www.mayoclinic.org/cancer-treatment/

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By